Also found in: Wikipedia.


(i-dur-sul-fase) ,


(trade name)


Therapeutic: replacement enzyme
Pharmacologic: enzymes
Pregnancy Category: C


Treatment of Mucopolysaccharidosis II (MPS II, Hunter syndrome).


Replaces an enzyme not present in Hunter syndrome. Absence of the enzyme results in cellular accumulation of aminoglycans, organomegaly and organ dysfunction.

Therapeutic effects

Improved walking capacity.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: unknownnown.
Half-life: 44–48 min.

Time/action profile

IVrapidend of infusionunknown


Contraindicated in: No known contraindications.
Use Cautiously in: Compromised respiratory function/acute respiratory disease (increased risk of infusion reactions); Severe genetic mutations (↑ risk of serious adverse reactions)Patients at risk for fluid overload, acute respiratory disorder, cardiac or respiratory illness (↑ risk of compromised cardiac or respiratory function) Obstetric: Use in pregnancy only if clearly needed; Obstetric: Use cautiously in lactation; Pediatric: Children <16 mo (safety not established).

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • malaise


  • hypertension


  • dyspepsia


  • cutaneous reactions (most frequent)


  • infusion site swelling


  • arthralgia (most frequent)


  • anaphylaxis (life-threatening)
  • fever (most frequent)


Drug-Drug interaction

None noted.


Intravenous (Adults and Children ≥5 yr) 0.5 mg/kg weekly


Solution for IV infusion (requires dilution): 2 mg/mL

Nursing implications

Nursing assessment

  • Observe for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing) during and for 24 hrs after infusion. Keep epinephrine, an antihistamine, corticosteroids, and resuscitation equipment close by in case of anaphylactic reaction.
  • Monitor for infusion-related reactions (headache, fever, rash, pruritus, erythema, urticaria, hypertension. Most reactions are managed with antihistamines and/or corticosteroids prior to or during infusions, slowing rate of infusion, and/or early discontinuation if reaction is serious.

Potential Nursing Diagnoses

Impaired physical mobility (Indications)


  • Patients with compromised respiratory function or acute respiratory disease are at increased risk of life-threatening infusion reactions. Consider delaying infusion in patients with concomitant acute respiratory and/or febrile illness.
  • Intermittent Infusion: Determine number of vials required for the dose ordered. If number of vials includes a fraction, round up to next whole number. Vials are for single use; discard remaining medication. Dilute each vial in 100 mL of 0.9% NaCl. Use an infusion set with a 0.2 micrometer filter for administration. Mix gently; do not shake solution. Solution is clear to slightly opalescent; do not administer solutions that are discolored or contain particulate matter. Solution may be stored in refrigerator for up to 48 hr. Discard solution of not administered or refrigerated within 8 hrs.
  • Rate: Administer at 8 mL/hr for first 15 min. If well tolerated, may increase by 8 mL/hr at 15 min intervals to administer total volume within desired time. Do not exceed 100 mL/hr. May slow, temporarily stop, or discontinue for that visit if infusion reactions occur. Administer total infusion over 1–3 hrs. May require longer times if infusion reactions occur; should not exceed 8 hrs.
  • Y-Site Incompatibility: Do not administer other medications or solutions in same tubing as idursulfase.

Patient/Family Teaching

  • Explain purpose of infusion to patient and parents.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Inform patient that a Hunter Outcome Survey was established to evaluate long term treatments. For information, visit or call 1–866–888–0660.

Evaluation/Desired Outcomes

  • Improved walking capacity in patients with Hunter syndrome.


a rarely used enzyme replacement.
indications This drug is used to treat mucopolysaccharidosis II.
contraindications Known hypersensitivity to this drug or other systemic antifungal or azoles, fungal meningitis, and onchomycosis or dermatomycosis in cardiac function prohibit its use.
adverse effects Adverse effects of this drug include insomnia, fever, rigors, weakness, anxiety, hypertension, hypotension, tachycardia, anemia, cramps, abdominal pain, flatulence, gynecomastia, impotence, decreased libido, malaise, hypokalemia, and tinnitus. Life-threatening side effects include GI bleeding, hepatotoxicity, toxic epidermal necrolysis, and rhabdomyolysis. Common side effects include headache, dizziness, nausea, vomiting, anorexia, diarrhea, pruritus, rash, edema, and fatigue.
Mentioned in ?
References in periodicals archive ?
There are potential infusion related adverse events(pyrexia, chills, hypertension,tachycardia, cutaneous reactions, headache, nausea, fatigue, malaise, joint pain, dyspnea, facial edema, dizziness and bronchospasm) for all seven FDA approved ERT products and the black box warnings (life-threatening anaphylactic reactions) for four FDA approved ERT products alglucosidasealfa - MyozymeA(r) and LumizymeA(r), idursulfase - ElapraseA(r), laronidase -AldurazymeA(r)).
03 Contract Award Notice - Successful Supplier(s): Supply of Idursulfase (Elaprase) concentrate for intravenous infusion 2mg/ml 3ml vial to Health Boards across NHS Scotland.
Assim, os profissionais que atendem os demais pacientes no Brasil organizaram, na maioria das vezes com o apoio financeiro das industrias farmaceuticas envolvidas na producao e comercializacao da laronidase, idursulfase e galsulfase, e mesmo de agencias publicas de fomento cientifico, um sistema informal que possibilita o diagnostico, sem custos para o paciente e para o medico assistente.
No Ministerio da Saude, a judicializacao de laronidase, idursulfase e galsulfase, medicamentos para as doencas do grupo das MPS, foi feita por 195 individuos beneficiados por 196 decisoes judiciais entre 2006 e 2010, que juntos consumiram R$ 219.
Therefore, comparison of the incidence of antibodies to Oncaspar[R] with the incidence of antibodies to other products may be misleading' Elaprase The data reflect the percentage of patients (idursulfase) whose test results were positive for antibodies to idursulfase in specific assays, and are highly dependent on the sensitivity and specificity of these assays.
Mecanismo Doencaalvo Nome do farmaco de acao Fabry Betagalsidase TRE Fabry Alfagalsidase TRE Fabry AT1001 Chaperona Gaucher Velaglucerase alfa (glicocerebrosidase TRE produzida em celulas humanas) Gaucher Glicocerebrosidase produzida em TRE celulas vegetais Gaucher Miglustate ISS Gaucher Genz-112638 ISS Gaucher AT2101 Chaperona MPS I Laronidase TRE MPS II Idursulfase TRE MPS VI Galsulfase TRE Niemann-Pick B Esfingomielinase recombinante TRE Niemann-Pick C Miglustate ISS Pompe Alglucosidase alfa([alpha]-glicosidase TRE acida produzida em celulas CHO) Pompe [alfa]-glicosidase acida recombinante TRE produzida a partir do leite de coelhos transgenicos Tay-Sachs (tardia) Miglustate ISS Tay-Sachs (tardia) Pirimetamina Chaperona Registro Doencaalvo Fase de desenvolvimento Anvisa?
Exclusive supply drugs: Idursulfase, for health centers in the Health Logistics Platform of Seville.